Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MENLO PARK, Calif., & NAPLES, Fla.--(BUSINESS WIRE)--GRAIL and Fountain Health announced a partnership that will offer Galleri® to Fountain Health customers at 100% coverage.

GRAIL and Fountain Health Insurance Partner to Provide Coverage of Galleri® Multi-cancer Early Detection Test

The news that the company's CFO is leaving has spooked investors. The stock has tumbled 15.7% since Thursday morning.

Illumina Will Be Fine Despite Recent Concerns, Says CEO

The genomic-sequencing company's CFO is unexpectedly leaving for another company.

Why Illumina Stock Is Sinking Today

SAN DIEGO , June 9, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami, Chief Strategy and Corporate Development Officer, will also serve as interim Chief Financial Officer while the company conducts a search for a permanent CFO. Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.

JOYDEEP GOSWAMI APPOINTED INTERIM CFO; SAM SAMAD TO DEPART ILLUMINA

SAN DIEGO , June 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and presentations it will make at the Advances in Genome Biology and Technology (AGBT) General Meeting, taking place June 6–9 in Orlando, Fla. Announcements will include new 2x300 base pair read lengths on NextSeq™ 1000 and 2000 systems, designed to expand the breadth of applications and support customers looking to scale from the MiSeq™ system.

Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL announced that the study design of the NHS-Galleri trial was presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

GRAIL and England's National Health Service (NHS) Present Trial Design for Largest Study of Multi-Cancer Early Detection Test at ASCO Annual Meeting

MENLO PARK, Calif. & NEW ORLEANS--(BUSINESS WIRE)--GRAIL and Ochsner Health announced a multi-faceted partnership to improve cancer detection rates in Louisiana using Galleri®.

GRAIL and Ochsner Health Launch New Initiatives to Improve Cancer Detection Rates in Louisiana

SAN DIEGO , June 2, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7 in Chicago. In addition, Illumina will host a related event, "Unlocking Precision Medicine: The Transformational Impact of Comprehensive Genomic Profiling," featuring Chief Medical Officer, Phil Febbo, MD; Kevin Keegan, Vice President and General Manager, Oncology; and a panel of leading oncologists from select community and academic programs.

Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO

AstraZeneca

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL announced a broad strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic assays.

GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer

Illumina (ILMN) GRAIL's recent collaboration is part of REFLECTION, a real-world observational study assessing the performance of the Galleri MCED test in clinical settings.

Illumina's (ILMN) GRAIL to Assess Galleri Test With New Deal

Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.

Here's Why Investors Should Retain Illumina (ILMN) Stock Now

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL collaborates with the U.S. Department of Veterans Affairs Veterans Health Administration and the Veterans Health Foundation to provide Galleri.

GRAIL Announces Collaboration With U.S. Department of Veterans Affairs and the Veterans Health Foundation to Evaluate Galleri® Multi-Cancer Early Detection Test

Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.

Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI

A European court will decide on July 13 whether U.S. life sciences company Illumina's $8 billion cash-and-stock takeover of Grail should be scrutinised by EU antitrust regulators, people familiar with the matter said on Wednesday.

EU court to rule July 13 on Illumina challenge of EU review of Grail -sources

Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.

Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger

FOSTER CITY, Calif.--(BUSINESS WIRE)--Illumina Ventures promotes Malek Faham to Chief Scientist, and adds Charles Lin as Principal and Dave Johnson as Entrepreneur in Residence.

Illumina Ventures Announces Promotion and Additions to its Investment Team

First companion diagnostic claim for Illumina's TruSight™ Oncology Comprehensive (EU) test enables targeted therapy with Bayer's VITRAKVI® (larotrectinib) for patients with NTRK fusion cancer SAN DIEGO , May 24, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.

Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy

We think that Illumina stock (NASDAQ: ILMN) currently is a better pick compared to the Walgreens stock (NYSE: WBA), despite it being the more expensive of the two, trading at 7.8x trailing revenues compared to 0.3x for Walgreens.

This Gene Sequencing Company Is A Better Pick Over Walgreens Stock

Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.

Illumina's (ILMN) GRAIL, Intermountain Healthcare Expand Tie-Up

Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient's cancer, which may influence choice of treatment based on cancer stage and type SAN DIEGO , May 18, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving the Western Pennsylvania area, today announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling (CGP) to enhance patient care. The collaboration will assess the value of in-house testing for both tissue and blood samples, versus sending those samples externally, and whether this approach may benefit cancer patients and the broader healthcare system.

Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care

MENLO PARK, Calif. & SALT LAKE CITY--(BUSINESS WIRE)-- #DetectCancerEarly--Intermountain Healthcare will offer Galleri®, GRAIL's multi-cancer early detection blood test, as a complement to existing single cancer screenings.

GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah

An analysis of 2 million Medicare beneficiaries establishes the cost of cancer by stage and time since diagnosis for 17 common cancers. The later the stage at diagnosis, the higher the cost, and this cost difference lasts for at least five years after diagnosis.

Comprehensive Study Establishes Cost of Late Detection and Treatment of Cancer

A jury in the U.S. District Court for the District of Delaware rendered a verdict that Illumina Inc (NASDAQ: ILMN) willfully infringed the U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics Inc. The jury awarded approximately $334 million to CGI in past.

Why Illumina Shares Are Plunging Today?

A Delaware jury on Friday ordered Illumina Inc to pay more than $333 million to a U.S. unit of Chinese genetic analysis company BGI Genomics after finding that Illumina's DNA-sequencing systems infringed two patents.

Illumina ordered to pay Chinese company $333 million in gene-sequencing patent case

Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.

News for Illumina Stock (ILMN)